OSLO, Norway, March 3, 2020 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage biotechnology company
developing immune activators to target hard-to-treat solid tumors,
today announces that it has completed patient enrollment in the
phase I trial with ONCOS-102 in combination with Keytruda
(pembrolizumab) in patients with advanced anti-PD1 checkpoint
inhibitor (CPI) refractory melanoma.
In this trial, ONCOS-102 immune activation is being tested in
patients with advanced, unresectable melanoma who have had disease
progression on treatment with anti-PD1 CPI. This is a particularly
challenging patient population, with few treatment alternatives
available. In July 2019, Targovax
reported encouraging results from part 1 of the trial - see
link to press release here.
Part 2 of this trial is testing an extended ONCOS-102 dosing
regimen with up to twelve injections compared to three injections
in part 1. The enrollment of 12 patients into part 2 of the trial
has now been completed. The last patients will complete their six
months treatment and data on a total of 21 patients are expected in
the second half of 2020.
The primary and secondary endpoints of the trial are to assess
safety, immune activation and clinical responses of ONCOS-102 and
Keytruda combination treatment. The main scientific aim is to test
the hypothesis that ONCOS-102 can immune activate anti-PD1
refractory patients to respond to re-challenge with an anti-PD1
CPI.
Magnus Jäderberg, CMO of Targovax, said: "We
are very pleased to have completed enrollment of our melanoma
trial. ONCOS-102 is currently one of the most clinically advanced
oncolytic viruses in this difficult to treat cancer, and therefore
a high priority for us. With this trial also being a proof of
concept trial, clinical and immune data from this study will not
just indicate whether ONCOS-102 in combination with CPIs can help
patients with hard to treat melanoma but potentially also other
tumor indications. Supportive data could open the path for a
registrational trial."
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-announces-completed-enrollment-in-the-oncos-102-trial-in-anti-pd1-refractory-melanoma,c3050994
View original
content:http://www.prnewswire.com/news-releases/targovax-announces-completed-enrollment-in-the-oncos-102-trial-in-anti-pd1-refractory-melanoma-301015035.html
SOURCE Targovax